201 related articles for article (PubMed ID: 28763145)
1. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Li J; Xu R; Xu J; Denda T; Ikejiri K; Shen L; Toh Y; Shimada K; Kato T; Sakai K; Yamamoto M; Mishima H; Wang J; Baba H
Cancer Sci; 2017 Oct; 108(10):2045-2051. PubMed ID: 28763145
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Koizumi W; Boku N; Yamaguchi K; Miyata Y; Sawaki A; Kato T; Toh Y; Hyodo I; Nishina T; Furuhata T; Miyashita K; Okada Y
Ann Oncol; 2010 Apr; 21(4):766-771. PubMed ID: 19828562
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.
Yoshino T; Hyodo I; Nishina T; Narahara H; Sugimoto N; Yoshisue K; Boku N
Cancer Chemother Pharmacol; 2017 Jan; 79(1):107-116. PubMed ID: 27933371
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
Wang ZQ; Zhang DS; Xu N; Luo DY; Deng YH; Wang FH; Luo HY; Qiu MZ; Li YH; Xu RH
Chin J Cancer; 2016 Jan; 35():8. PubMed ID: 26739998
[TBL] [Abstract][Full Text] [Related]
5. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Yamaguchi K; Taniguchi H; Komori A; Narita Y; Nitta S; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K; Mori K; Igarashi Y
BMC Cancer; 2015 Aug; 15():601. PubMed ID: 26311588
[TBL] [Abstract][Full Text] [Related]
6. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
[TBL] [Abstract][Full Text] [Related]
10. A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
Lu M; Wang Y; Liu W; Bai C; Xu J; Shen L
Hepatogastroenterology; 2014 Jun; 61(132):1018-23. PubMed ID: 26158159
[TBL] [Abstract][Full Text] [Related]
11. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Nakai Y; Isayama H; Saito K; Sasaki T; Takahara N; Hamada T; Mizuno S; Miyabayashi K; Yamamoto K; Mohri D; Kogure H; Yamamoto N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2014 Nov; 74(5):911-5. PubMed ID: 25143299
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer.
Naito T; Seto T; Takeda K; Goto K; Okamoto I; Nakagawa K; Ohba T; Murakami H; Takahashi T; Yamanaka T; Yamamoto N
Lung Cancer; 2014 Dec; 86(3):339-43. PubMed ID: 25453619
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
[TBL] [Abstract][Full Text] [Related]
15. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Bin Q; Li J; Liao C; Cao Y; Gao F
Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer.
He MM; Wang F; Jin Y; Yuan SQ; Ren C; Luo HY; Wang ZQ; Qiu MZ; Wang ZX; Zeng ZL; Li YH; Wang FH; Zhang DS; Xu RH
Cancer Sci; 2018 Nov; 109(11):3575-3582. PubMed ID: 30281875
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Mizushima T; Tamagawa H; Matsuda C; Murata K; Fukunaga M; Ota H; Hasegawa J; Tsujie M; Fukuzaki T; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Oncology; 2015; 89(3):152-8. PubMed ID: 25967649
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]